Pages that link to "Q36168439"

The following pages link to Hospitalisation Utilisation and Costs in Schizophrenia Patients in Finland before and after Initiation of Risperidone Long-Acting Injection (Q36168439):

Displaying 9 items.

• Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis (Q36550998) (← links)
• Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia (Q36798150) (← links)
• Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia (Q37007725) (← links)
• The Cost of Inpatient Care of Schizophrenia and Treatment Schedules Used in German Academic Center: Kiel. (Q37306488) (← links)
• The Cost of Relapse in Schizophrenia. (Q38769604) (← links)
• Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia. (Q38851847) (← links)
• Psychotic disorder is an independent risk factor for increased fasting glucose and waist circumference (Q40119718) (← links)
• Risperidone long-acting injection and 1-year rehospitalization rate of schizophrenia patients: A retrospective cohort study (Q41204400) (← links)
• Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia: results from a prospective, 1-year, non-interventional study (InORS). (Q45170470) (← links)